| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2003 | US6559160 These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, |
| 05/06/2003 | US6559159 Kappa opioid receptor ligands |
| 05/06/2003 | US6559158 A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat |
| 05/06/2003 | US6559157 Dihydronaphthalene compounds |
| 05/06/2003 | US6559155 Pyrimidinone derivatives for the treatment of atherosclerosis |
| 05/06/2003 | US6559154 Composition of sodium channel blocking compound |
| 05/06/2003 | US6559153 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders |
| 05/06/2003 | US6559152 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 05/06/2003 | US6559150 Growth hormone secretagogues |
| 05/06/2003 | US6559148 Administering a therapeutically effective amount of a compound which is a P2Y purinoreceptor antagonist such as Basilen Blue |
| 05/06/2003 | US6559147 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 05/06/2003 | US6559146 Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins |
| 05/06/2003 | US6559145 Heterocycle carboxamides as antiviral agents |
| 05/06/2003 | US6559143 Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction |
| 05/06/2003 | US6559142 Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis |
| 05/06/2003 | US6559141 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| 05/06/2003 | US6559139 Combination chemotherapy |
| 05/06/2003 | US6559138 For treatment of osteoporosis, the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss |
| 05/06/2003 | US6559137 Characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient |
| 05/06/2003 | US6559135 Per-(3-6-anhydro)cyclodextrins derivatives, preparation and use thereof for separating ions |
| 05/06/2003 | US6559133 Administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular or acute coronary syndromes alone or with thromolytic, anticoagulants, antithrombotic or antiplatelet agents |
| 05/06/2003 | US6559131 Fucan increases the expression and/or the activity of a fibroblastic metalloproteinase or that inhibits leukocyte elastase, or both for treating a periodontal pathology or a dermal pathology |
| 05/06/2003 | US6558950 Nucleotide sequences coding polypeptide for use in the treatment of programed cell death defects |
| 05/06/2003 | US6558932 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/06/2003 | US6558919 Nucleotide sequences coding polypeptide for use in the prevention and treatment of infections |
| 05/06/2003 | US6558905 Diagnosing osteoporosis in humans; obtain tissue sample, extract nucleotide sequences, digest, incubate with marker probe, detect presence of preferential allele, presence of allele indicate osteoporosis |
| 05/06/2003 | US6558711 Composition and method for reducing the risk of carcinogenesis |
| 05/06/2003 | US6558710 Zinc oxide, its hydrated complex with glycine or lycine and free anhydrous glycine; healing skin; minimizing irritation without loss of efficacy |
| 05/06/2003 | US6558708 Administering agonists or antagonists of serotonin, peptide YY, calcitonin gene related peptide, adrenergic and/or opioid receptors |
| 05/06/2003 | US6558707 Micronized particles in carrier such as a purified, micro-crystalline or alkylated cellulose |
| 05/06/2003 | US6558704 Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient |
| 05/06/2003 | US6558703 Porous hydroxyapatite particles as carriers for drug substances |
| 05/06/2003 | US6558702 Mixture of polymer and bisphosphonate compound |
| 05/06/2003 | US6558701 Multilayer tablet for administering a fixed combination of tramadol and diclofenac |
| 05/06/2003 | US6558696 Desoxypeganine |
| 05/06/2003 | US6558695 Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| 05/06/2003 | US6558689 For use in spraying into the nose and mouth to protect the mucosa from noxious viruses, bacteria and fungi and excessive drying, in situations of high risk, such as the cabins of commercial aircraft |
| 05/06/2003 | US6558688 Ocular tissue regeneration inducer |
| 05/06/2003 | US6558680 Cosmetic and dermatological preparations based on O/W emulsions |
| 05/06/2003 | US6558671 Tumor specific immunogens of modified naturally occurring epitope SEQ ID NO:19, 37 or 10 |
| 05/06/2003 | US6558666 Chromium-containing carbohydrase enzyme food supplement composition |
| 05/06/2003 | US6558663 Promoting tolerance and inhibiting natural killer cell mediated attack in human recipient to a swine graft |
| 05/06/2003 | US6558657 Synthetic polymer, carbohydrate or protein substituted with disulfide moiety that inhibits fat hydrolysis |
| 05/06/2003 | US6558656 Oral and topical compositions and methods related thereto in the treatment of acne |
| 05/06/2003 | US6558655 Substituted with at least one hydroxyl group or alkoxy radical. |
| 05/06/2003 | US6558653 That uses a dye composition and laser energy |
| 05/06/2003 | US6558651 Crystalline salbutamol sulphate and 1,1,1,2-tetrafluoroethane; consistent delivery from metered dose inhaler |
| 05/06/2003 | CA2268166C Pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof |
| 05/06/2003 | CA2253362C Intracoronary stents containing quinazolinone derivatives |
| 05/06/2003 | CA2244194C Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 05/06/2003 | CA2212779C Compositions comprising nanoparticles of nsaid |
| 05/06/2003 | CA2186017C Soap composition |
| 05/06/2003 | CA2181048C A method for sustained and extended corneal analgesia |
| 05/06/2003 | CA2126691C Gapped 2' modified oligonucleotides |
| 05/06/2003 | CA2117136C Cosmetic applicator useful for cleansing, moisturizing and protecting the skin from diaper rash |
| 05/06/2003 | CA2087789C Oral composition |
| 05/06/2003 | CA2056068C Process |
| 05/06/2003 | CA2047802C Pharmaceutical compositions |
| 05/02/2003 | EP1306437A2 Delta opioid receptor genes |
| 05/02/2003 | EP1306387A1 Drugs or cosmetics |
| 05/02/2003 | EP1306378A1 Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient |
| 05/02/2003 | EP1306377A2 Pyridyl-oxazoles and their use as cytokines inhibitors |
| 05/02/2003 | EP1306376A1 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| 05/02/2003 | EP1306375A1 Salts of benzimidazole compound and use thereof |
| 05/02/2003 | EP1306373A1 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 05/02/2003 | EP1306368A2 3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 05/02/2003 | EP1306367A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 05/02/2003 | EP1306094A1 Preventives or remedies for obesity or fatty liver |
| 05/02/2003 | EP1306093A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient |
| 05/02/2003 | EP1306090A1 Cosmetics or dermatological preparations containing polymers having phosphorylcholine side chain |
| 05/02/2003 | EP1306089A1 Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists |
| 05/02/2003 | EP1306088A1 Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic |
| 05/02/2003 | EP1306087A1 Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient |
| 05/02/2003 | EP1306086A2 Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders |
| 05/02/2003 | EP1306085A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor |
| 05/02/2003 | EP1306083A1 Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion |
| 05/02/2003 | EP1306082A1 Pressurized metered dose inhalers and pharmaceutical aerosol formulations |
| 05/02/2003 | EP1306081A1 Cosmetic use of DHEA-derivatives |
| 05/02/2003 | EP1306067A1 Method for damaging thermo non-tolerance pathologic structures of a warm-blooded organism |
| 05/02/2003 | EP1305418A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein |
| 05/02/2003 | EP1305382A1 Purifying crude pufa oils |
| 05/02/2003 | EP1305330A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| 05/02/2003 | EP1305329A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 05/02/2003 | EP1305319A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 05/02/2003 | EP1305318A1 Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo 2,1-b] 1,3]benzotiazepines |
| 05/02/2003 | EP1305317A1 Dihydroporphyrin derivatives and their uses |
| 05/02/2003 | EP1305316A2 Azabicyclic derivatives and their therapeutic use |
| 05/02/2003 | EP1305314A1 Crystalline therapeutic agent |
| 05/02/2003 | EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors |
| 05/02/2003 | EP1305312A1 Tartrate salts of thiazolidinedione derivative |
| 05/02/2003 | EP1305311A1 Tartrate salt of thiazolidinedione derivative |
| 05/02/2003 | EP1305310A1 Tartrate salts of thiazolidinedione derivative |
| 05/02/2003 | EP1305309A1 Lactam inhibitors of factor xa which are useful for the treatment of thrombosis |
| 05/02/2003 | EP1305308A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| 05/02/2003 | EP1305307A1 Indole derivatives useful for the treatment of cns disorders |
| 05/02/2003 | EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 05/02/2003 | EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| 05/02/2003 | EP1305303A1 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE |
| 05/02/2003 | EP1305301A1 Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 05/02/2003 | EP1305300A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments |